Acurx Pharmaceuticals, Inc. has announced the unexpected passing of Board member Thomas Harrison on November 18, 2026. This event is significant as it raises concerns about leadership stability within the company and its strategic direction moving forward.

Acurx Pharmaceuticals, founded in 2021, operates in the pharmaceutical preparations industry, as indicated by its SIC code 2834. The company is publicly traded under the ticker ACXP on the Nasdaq exchange. Recent filings include an 8-K report on November 20, 2026, and a 10-Q report on November 12, 2026, among others.

The SEC filing details that Harrison had been a member of the Board of Directors since 2021. The company expressed its deep regret over his passing, stating, "Acurx Pharmaceuticals, Inc. deeply regrets to announce that Thomas Harrison, a member of the Board of Directors of the Company since 2021, unexpectedly passed away November 18, 2026." This statement reflects the company's acknowledgment of Harrison's contributions and the impact of his loss.

This unfortunate event may affect various stakeholders, including employees, investors, and partners, as they navigate the implications of such a leadership change. The pharmaceutical industry often relies on strong governance and strategic vision, making the loss of a board member particularly impactful.

As of now, the filing does not specify what steps Acurx Pharmaceuticals will take in response to Harrison's passing. There is no indication of immediate succession plans or changes to the board structure. Stakeholders will be watching closely for any updates regarding the company's governance and future direction.